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Introduction
1. Background, purpose, and scope of the clinical 
practice guidelines for gastric cancer
Recently, the cancer incidence rate has increased in South 
Korea. According to data from the National Cancer Information 
Center, under the Ministry of Health and Welfare, the rate has 
significantly increased by 3.3% annually during 1999~2008.1,2 Ac-
cording to 2008 data, 1 in 3 Koreans might have cancer, with prob-
abilities of 37.2% for men, assuming a mean life expectancy of 77 
years, or 30.5% for women, assuming a mean life expectancy of 
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83 years. The effective treatment has increased the survival rate of 
gastric cancer patients. However, the prognosis remains relatively 
poor, with a 5-year survival rate of 63.1% during 2004~2008.1 Ac-
cording to the data on the cause of mortality, 28.6% of the 246,942 
total cancer-related deaths in 2009 were caused by malignant 
neoplasms, among which gastric cancer was the leading cause of 
cancer-related deaths.2 Economic burden related with gastric can-
cer is considerably high. In 2007, the Health Insurance Review and 
Evaluation Service indicated that the total medical costs incurred 
by gastrointestinal diseases (excluding meals, selective treatment 
fees, and medication costs from the total expenses paid for Health 
Insurance Reimbursement) were approximately 3.65 trillion wons. 
The medical costs incurred by malignant gastrointestinal diseases 
accounted for 36.6% of the above amount, and gastric cancer ac-
counted for 10.9% (390 billion wons) of all gastrointestinal diseases, 
the highest percentage for a single disease (unpublished data).
The present clinical practice guideline is intended for use in both 
male and female adult patients with gastric cancer. This guideline, 
which is based on domestic and overseas evidences, have been de-
veloped to suit Korea’s current medical practices and to ensure their 
widespread adoption in clinical practice. It was intended to help all 
medical staffs at the primary, secondary, and tertiary care medical 
institutions including physicians, surgeons, radiologists, patholo-
gists, family doctors, and general practitioners. Additionally, it was 
designed to allow patients and populations to find optimum care 
by providing adequate medical information. Furthermore, it was 
intended for widespread adoption in order to increase the standard 
of gastric cancer treatment, thereby contributing to improvement in 
the patients’ quality of life, as well as in the national health care. It 
will also provide information on clinical practices and principles for 
medical residents and other medical staffs. 
The present guideline is specific and comprehensive for gastric 
cancer diagnosis and treatment; however, it does not address issues 
related to prevention, screening, and care of pediatric patients. In 
addition, it does not address controversial issues with inadequate evi-
dence. However, the nominal group technique was applied to include 
consensus of the clinically important issues with weak evidences. 
2. Composition and progress of guideline develop­
ment group
The present guideline was prepared as a designated project as-
signment (no. 1020440) under the Research and Development Pro-
gram for Cancer Control, conducted by the Ministry of Health and 
Welfare, South Korea. This guideline was prepared in an integrated 
and comprehensive manner through an interdisciplinary approach 
that included the Korean Academy of Medical Sciences, the Korean 
Association of Internal Medicine, the Korean Society for Radiation 
Oncology, the Korean Society of Pathologists, the Korean College 
of Helicobacter and Upper Gastrointestinal Research, the Korean 
Society of Gastrointestinal Endoscopy, the Korean Society of Gas-
troenterology, the Korean Cancer Association, the Korean Society 
of Radiology, the Korean Gastric Cancer Association, and the Ko-
rean Society of Nuclear Medicine, along with the participation of 
experts in the guideline development methodology. To develop this 
guideline, the Organizing Committee for Clinical Practice Guide-
lines for Gastrointestinal Cancer, the Development Committee for 
Standard Clinical Practice Guidelines for Gastric Cancer, and the 
Review Committee for Standard Clinical Practice Guidelines for 
Gastric Cancer were established, and the members were recom-
mended by each participant associations and societies (http://www.
guideline.or.kr). 
3. Literature search, evaluation, and preparation of 
recommendations
The fundamental and important issues concerning gastric cancer 
diagnosis and treatment were selected as key questions according to 
the patient, intervention, comparator, and outcome (PICO). Search 
terms for each respective key question were selected according to 
the medical subject headings (MeSH) terms of National Library of 
Medicine. For each key question, the inclusion/exclusion criteria 
were determined and the search words were properly combined 
to conduct the literature search. PubMed, MEDLINE and the Co-
chrane Library were used for the international literature search, 
while KoreaMed was used for the purpose of domestic literature 
search. The literature search was conducted only for the documents 
published from 1980~2011 in either English or Korean. 
To evaluate the validity of the documents selected as evidence, a 
systematic and consistent evaluation method was adopted. In order 
to apply different evaluation methods, the documents were classified 
according to the study design.3 To evaluate randomized controlled 
studies, the risk of bias (ROB) method of Cochrane Collaboration 
was adopted.4 The Review Manager (RevMan) 5 (The Nordic Co-
chrane Centre, The Cochrane Collaboration, 2012) and GRADEpro 
program (Jan Broeck, Andrew Oxman, Holger Schünemann, 2008) 
were used to arrange the evidence and evidence summary table.5 
To evaluate non-randomized controlled studies, the Newcastle-
Ottawa evaluation scale was applied. To evaluate diagnostic studies, 
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) 
tool was used;6 accordingly, the evaluations were classified as ‘yes’, 
‘no’, or ‘not clear’ for 11 assessable items among the 14 items.
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The Grading of Recommendations, Assessment, Development, 
and Evaluation (GRADE) method was used for the evidence sum-
mary.7,8 Levels of evidence of studies were ranked according to the 
type of research, with a high level evidence for randomized clinical 
trials and a low level evidence for observational studies. Next, the 
qualitative level of the corresponding study was increased or de-
creased after considering the factors that influenced the quality of 
each study. The levels of evidence were classified as high-quality, A; 
moderate-quality, B; low-quality, C; and very low-quality, D. For 
cases with no evidence or difficult to analyze, a fifth classification (no 
evidence or difficult to analyze, E) was added and used (Table 1).
For the grading of recommendations, (1) a balance of desir-
able and undesirable effects, (2) evidence quality, and (3) values 
and preferences were taken into account, according to the GRADE 
method. Any area with difficult-to-determine recommendations is 
not mentioned in the present guideline, but will be reviewed during 
the next guideline development. The grades of recommendations 
are divided into (1) strong recommendations and (2) weak recom-
mendations (Table 1). A strong recommendation indicates that it is 
strongly recommended for most patients because compliance with 
this recommendation for a specific intervention will result in a de-
sirable rather than an undesirable effect, along with a high quality 
of evidence and a better value and preference, compared to other 
interventions. A weak recommendation indicates that it is better for 
many patients to comply with this recommendation because despite 
rather weak evidence, a desirable effect has been shown. With a 
weak recommendation, some patients or medical staff might select 
different interventions according to the values or preferences.
4. Review and approval process
Based on the present guideline as developed by the Develop-
ment Committee and reviewed by the Review Committee, a public 
hearing was held on October 29, 2011. The concerned experts, 
patients and other interested people participated the hearing. Revi-
sions that reflected the opinions expressed in the public hearing 
were made. This guideline was then approved by the Korean As-
sociation of Internal Medicine, the Korean Cancer Association, the 
Korean Society of Pathologists, the Korean College of Helicobacter 
and Upper Gastrointestinal Research, the Korean Society of Gas-
troenterology, the Korean Society of Gastrointestinal Endoscopy, 
the Korean Society of Radiology, the Korean Surgical Society, the 
Korean Gastric Cancer Association, the Korean Society for Radia-
tion Oncology, and the Korean Society of Nuclear Medicine.
5. Renewal procedure and monitoring
The present guideline for gastric cancer will be available free of 
cost at the web sites of the Korean Academy of Medical Sciences 
(http://www.kams.or.kr/), the Korean Association of Internal 
Medicine (http://www.kaim.or.kr/), the Korean Society for Radia-
tion Oncology (http://www.kosro.or.kr/), the Korean Society of 
Pathologists (http://www.pathology.or.kr/), the Korean Society of 
Helicobacter and Upper Gastrointestinal Research (http://hpylori.
or.kr/), the Korean Society of Gastrointestinal Endoscopy (http://
www.gie.or.kr/), the Korean Society of Gastroenterology (http://
www.gastrokorea.org/), the Korean Cancer Association (http://
www.cancer.or.kr/), the Korean Society of Radiology (http://www.
radiology.or.kr/), the Korean Gastric Cancer Association (http://
www.kgca-i.or.kr/), and the Korean Society of Nuclear Medicine 
(http://www.ksnm.or.kr/), as well as through Facebook and Twit-
ter, where monitoring can be processed and all opinions regarding 
this guideline are welcome. The guidelines will be renewed in 3 to 
5 years based on the accumulated clinical evidence. 
6. Absence of conflicts of interest 
The present guideline was prepared as a designated project as-
signment, entitled the “Development of clinical practice guidelines 
methods for gastrointestinal cancer and clinical practice guidelines 
for gastric cancer/colon cancer” (no. 1020440), under R&D Pro-
gram for Cancer Control, conducted by the Ministry of Health 
and Welfare. The members comprised of a principal investiga-
tor, Hyeong Sik Ahn (Department of Preventive Medicine, Korea 
University College of Medicine, Seoul), a principal investigator for 
gastric cancer guideline, Jae Gyu Kim (Department of Medicine, 
Chung-Ang University College of Medicine, Seoul), and a principal 
investigator for colon cancer guideline, Jun Won Uhm (Department 
of Surgery, Korea University College of Medicine, Seoul). The con-
tents of the present guideline were not influenced by the opinions 
of financially sponsoring entities. All of the members who partici-
Table 1. Levels of evidence and grades of recommendation 
Levels of evidence 
A. High-quality evidence
B. Moderate-quality evidence
C. Low-quality evidence
D. Very low-quality evidence
E. No evidence or difficult to analyze
Grades of recommendation 
1. Strong recommendation 
2. Weak recommendation
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pated in the development of the present guideline have submitted 
a confirmatory document with their signatures to assure that there 
were no conflicts of interest. None of the participants were involved 
in issues related to conflicts of interest.
7. Limitations of the present guideline
One of the major limitations of the present guideline is that 
there is not enough evidences in Korea. Data from studies in other 
countries may be slightly different in terms of epidemiological and 
clinical aspects. Considering the established therapeutic efficacy of 
current treatment methods, it is difficult to conduct new random-
ized controlled studies in some areas because of the ethical issues.
Endoscopic diagnosis
1. Conventional endoscopy
1) Upper gastrointestinal endoscopy and biopsy
Upper gastrointestinal endoscopy is the primary tool for the di-
agnosis of gastric cancer. By using the proper technique such as air 
infusion and removal of mucus, it is possible to observe the entire 
stomach clearly. One of the major advantages of endoscopy is that 
tissue sampling can be performed immediately by using biopsy 
forceps. The recently introduced magnifying endoscopy may help 
to observe the gastric lesion. 
To achieve the best results, endoscopy should be performed by 
properly trained endoscopists using appropriate endoscopic devices. 
Biopsy is necessary because there are limitations to the sensitivity 
and specificity of direct observation for diagnosing gastric cancer.9 
Normally, acquisition of more than 4 tissue samples is recom-
mended in order to increase the diagnostic accuracy. However, a 
fewer number of samples might be enough in patients considering 
endoscopic resection. Biopsy has a low sensitivity for detecting 
Borrmann type IV advanced gastric cancers. Endoscopic clips or 
dye injection can be used to determine the resection margin during 
the surgery.10 If it is difficult to localize the cancer lesion, as in rare 
cases, an intraoperative endoscopy can be performed.11
Recommendation: Upper gastrointestinal endoscopy is the pri-
mary diagnostic tool for gastric cancer (Recommendation Grade 1, 
Evidence Level E).
Recommendation: During upper gastrointestinal endoscopy, bi-
opsies of suspicious or possible gastric cancer lesions should be 
performed (Recommendation Grade 1, Evidence Level E).
2) Chromoendoscopy
Chromoendoscopy is easy and simple method that allows better 
visualization of the lesions with unclear color changes or minute 
surface irregularities. It is also useful in determining the lateral bor-
ders during endoscopic submucosal dissection (ESD). Dyes include 
methylene blue, indigocarmine, acetic acid, and crystal violet, and 
among them, indigo carmine is the most commonly used.12 After 
indigocarmine spraying, the dye fills the depressed mucosal sites, 
thus highlighting the surface irregularities. Such characteristics can 
help to estimate the depth of invasion of early gastric cancers (EGCs) 
and to determine the range of resection for endoscopic therapies.
Recommendation: Chromoendoscopy is useful in the determina-
tion of the lateral margin during endoscopic resection of early 
gastric cancer (Recommendation Grade 2, Evidence Level E).
2. Endoscopic ultrasonography 
Endoscopic ultrasonography (EUS) can be used to evaluate the 
depth of invasion of gastric cancers and the presence of local lymph 
node metastases. Because of the widespread use of laparoscopic 
surgery for EGC, evaluation of the stage of gastric cancer before 
therapy has become more important. A recent meta-analysis13 of 
54 studies, including 5,601 gastric cancer patients, showed that EUS 
had a relatively good sensitivity and specificity for differentiating 
between T1 to 2 and T3 to 4 lesions (0.86 and 0.91, respectively). 
However, the sensitivity and specificity for detecting lymph node 
metastases were lower (0.69 and 0.84, respectively).13 According to 
a recent Korean study,14 which compared the accuracies of white 
light endoscopy and EUS, the accuracy of white light endoscopy 
for predicting the depth of invasion of EGCs was 73.7%, while that 
of EUS was only 67.4%. Therefore, the usefulness of endoscopic 
ultrasonography before endoscopic therapy for gastric cancer re-
mains controversial.
Recommendation: In some patients, endoscopic ultrasonography 
(EUS) is useful in addition to white light endoscopy and CT be-
fore endoscopic or surgical resection of gastric cancer (Recom-
mendation Grade 2, Evidence Level D).
Radiology
1. Upper gastrointestinal series
The upper gastrointestinal series is a radiologic test that is 
widely used for the diagnosis of gastric cancer as it is safe and non-
invasive without the need for specific preparation. It is useful as a 
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preoperative test because of its high sensitivity and the ability to vi-
sualize the lesion location accurately and objectively.15,16 To perform 
an upper gastrointestinal series, it is important to obtain appropriate 
mucosal coating and gastrointestinal distention. For this purpose, 
a 240% weight per volume (w/v) high-density barium solution is 
generally used in gastrointestinal series. To ensure the accuracy of 
the upper gastrointestinal series, a single-contrast study including 
the compression and mucosal relief views should be combined with 
a double-contrast study that uses a high concentration of barium to 
coat the mucosa via air distention.17
Recommendation: Upper gastrointestinal series is useful for the 
diagnosis of gastric cancer (Recommendation Grade 1, Evidence 
Level C).
2. Computed tomography 
From the late 1970s, computed tomography (CT) is a diagnostic 
and preoperative test for detecting gastrointestinal tumors includ-
ing gastric cancer. To date, special CT techniques for evaluating 
the stomach have been widely used to detect and diagnose gastric 
cancers, to determine the optimal treatment method via accurate 
staging, and to identify therapeutic effects after surgery or anti-
cancer treatments. After the multidetector row CT (MDCT) was 
introduced, the diagnostic accuracy has increased and the detection 
of small lesions, including EGCs, has improved.
1) Multidetector row computed tomography 
After the introduction of MDCT, the z-axis resolution im-
proved, and thus the ambiguity of lesions due to partial volume av-
eraging, which was considered as the disadvantage of conventional-
type single-channel helical CT, was decreased. 
When using MDCT to diagnose gastric cancer, according to 
related literatures, at least a 4-channel MDCT is required, with a 
detector collimation ≤2.5 mm, an imaging section thickness ≤5 
mm, and the administration of approximately 500 ml of water or an 
effervescent agent; the patient is then instructed to change position 
until each part of the stomach is properly distended.18-20 Addition-
ally, it is better to perform dynamic CT after contrast enhancement 
because arterial-phase imaging allows easy detection of enhanced 
mucosal lesions of the stomach, while portal venous-phase imaging 
provides more accurate information including the depth of invasion 
of gastric cancer and the involvement of adjacent organs and facili-
tates the evaluation of lymph node metastases. In addition, delayed-
phase imaging might also be useful because in some cases there is 
enhanced fibrosis surrounding the gastric cancer, thus allowing a 
more accurate evaluation of tumor infiltration into the gastric wall. 
The reconstruction of arterial-phase and portal venous-phase 
images will permit CT angiography, which provides preoperative 
evaluation of perigastric blood vessels.
Upon examining the reports of preoperative tumor node metas-
tasis (TNM) staging via MDCT, the accuracies ranged from 67.9% 
to 90.9% for T (median value, 82.1%) and from 56.9% to 86% for 
N (median value, 69.5%). In particular, the specificity for T4, which 
determines whether surgery is indicated, ranged from 81.8% to 
99.4% (median value, 96.5%).18,20-24 Nevertheless, CT allows clini-
cians to diagnose advanced gastric cancer that has spread to the 
peritoneum or shows distant metastases, thereby preventing unnec-
essary surgeries. 
CT is also useful for evaluating the therapeutic effects after an-
ticancer therapy. The Response Evaluation Criteria in Solid Tumors 
(RECIST), which is used to evaluate response to treatment in solid 
cancers, states that CT is among the most useful modalities, along 
with magnetic resonance (MR) for evaluating the sizes of solid tu-
mors.25
Recommendation: CT should be performed for the preoperative 
staging of gastric cancer (Recommendation Grade 1, Evidence 
Level D).
2) Three­dimensional computed tomography gastrogra­
phy; virtual gastroscopy
This technique utilizes the 3-dimensional reconstruction of 
CT images to provide similar imaging to the upper gastrointestinal 
series or endoscopy. Its advantages include 3-dimensional repre-
sentation of the anatomical location of gastric cancers, facilitation 
of surgical planning, and the ability to detect depressed areas or 
changes in gastric mucosal folds that are difficult to observe in 
cross-sectional CT images; thus helping in identifying small lesions 
on the gastric mucosal surface in EGC.19
3. Magnetic resonance imaging 
Magnetic resonance imaging facilitates the diagnosis of extra-
serosal invasion or invasion into adjacent organs and the identifica-
tion of distant metastasis, and it is therefore useful in preoperative 
staging of gastric cancer. In particular, it has been widely used for 
the evaluation of liver metastases. Recently, liver-specific MR con-
trast agents have been developed and this allows us to achieve more 
accurate diagnoses of hepatic metastases in the future.26
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Recommendation: In some patients, liver magnetic resonance im-
aging (MRI) with contrast enhancement is useful for the diagnosis 
of liver metastasis of gastric cancer (Recommendation Grade 2, 
Evidence Level E).
Nuclear imaging
1. Role of [18F]­fluorodeoxyglucose positron emission 
tomography/computed tomography in the diag­
nosis of gastric cancer 
Although [18F]-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) is increasingly being 
adopted for the diagnosis of cancer and determination of thera-
peutic effects and staging, its role in detection of primary lesions is 
limited in some cases. According to the existing literature, the PET 
detection rate of EGC is less than 50%, and therefore PET alone 
is not recommended for gastric cancer screening in asymptomatic 
patients.27 In a study on the diagnosis of advanced gastric cancer, 
the success rate of PET in establishing the diagnosis ranged from 
62% to 98% because FDG uptake varies according to the charac-
teristics of gastric cancer.28-31 For example, PET/CT shows strong 
FDG uptake in the intestinal type gastric cancer and demonstrates 
high sensitivity, while a relatively low sensitivity was reported in 
diffuse-type tumors with a low level of FDG uptake.32 Considering 
the above findings, endoscopy and barium upper gastrointestinal 
series are still considered to be more effective for diagnosing EGC.
2. Staging and prediction of prognosis 
FDG PET/CT has a limited role in the detection of early 
primary gastric cancers. However, this is the same as that with 
contrast-enhanced CT, because it is difficult to evaluate primary 
tumors accurately due to the characteristics of the stomach. Ad-
ditionally, according to the pathologic evaluation of biopsies, the 
cell densities and the degree of malignancies are not uniform;32,33 
and therefore although PET/CT allows evaluation of the degree of 
metabolic activity and targets the highly malignant areas, its role is 
still limited with regard to accurate measurement of the depth of 
invasion into the gastric wall.
Next, when evaluating invasion into adjacent lymph nodes, the 
ability of PET to evaluate glucose metabolism is expected to allow 
more accurate detection of metastases to the local lymph nodes. 
According to Mochiki et al.,31 the diagnostic performance of PET 
for N1 lymph nodes is not satisfactory, but this might have little 
clinical significance because these lymph nodes will be resected 
during gastric cancer surgery. On the other hand, invasion of lymph 
nodes in the N3 group is classified as distant metastasis, and it is 
very important to determine distant metastasis accurately. Yun et 
al.34 reported that PET might provide useful information on distant 
lymph node invasion. 
In a study by Hillner et al.35 of 3,025 gastric cancer patients, dis-
tant metastases to other internal organs was evaluated, and patient 
management was altered significantly after the PET results in 37% 
of cases and PET showed better results than the conventional tests 
in the detection of liver metastases.36 In terms of skeletal evaluation, 
bone scanning still plays an important role and PET scanning can 
play a compensatory role in the detection of osteolytic bone metas-
tasis.29
In PET scanning, the degree of FDG uptake in primary gastric 
cancer is expected to be an additional predictive factor along with 
the conventional anatomical imaging-adapted TNM staging.32,33 
Additionally, peritoneal metastasis is also one of the important 
prognostic factors of gastric cancer and PET has a higher specific-
ity (99%), lower sensitivity (35%), and equal accuracy when com-
pared to CT for detection of peritoneal metastasis.37
Recommendation: In some patients, fluorodeoxyglucose/positron 
emission tomography/computerized tomography (FDG PET/CT) 
is useful for gastric cancer staging (Recommendation Grade 2, 
Evidence Level D).
3. Evaluation of recurrence
Postoperative evaluation of recurrence is very important in the 
management of gastric cancer. Sites of gastric cancer recurrence 
include adjacent organs, lymphatic system, blood circulation, and 
peritoneum. Consequently, recurrence sites include the local area, 
liver, lungs, skeletal system, peritoneum, and many other sites. 
Changes in the anatomical structure after gastric surgery can make 
it difficult to diagnose recurrence accurately in many cases. Some 
studies have reported that PET is better than conventional CT in 
terms of specificity and positive predictive value.33,38 Several stud-
ies reported that PET scanning after gastric distension due to water 
intake is useful for determining postoperative recurrence.39 Accord-
ing to the recent studies that assessed PET/CT, PET generally pro-
vides better results for the evaluation of gastric cancer recurrence 
compared to contrast-enhanced CT40 and this might be due to the 
combination of anatomic and functional data.
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Recommendation: In some patients, FDG PET/CT is useful 
for the evaluation of recurrence after surgery (Recommendation 
Grade 2, Evidence Level D).
4. Determination of therapeutic effects
During gastric cancer therapy, each individual patient presents 
with a different gastric cancer cell type, degree of differentiation, 
malignant potential of tumors, and depth of invasion, and therefore, 
a careful approach is essential in selecting anticancer drugs. Ott et 
al.39 performed baseline PET scans and additional PET scans after 
2 to 3 cycles of chemotherapy, and they proposed that the thera-
peutic effects of anticancer drugs can be determined by comparison 
of these two scans.39 Recently, many reports have suggested that 
the efficacy of therapeutic options can be determined by evaluat-
ing not only changes in size, but also changes in lesion metabolism. 
Therefore, the role of FDG PET/CT in management of gastric 
cancer will continue to expand in the future.
Surgery
1. Principles of gastric cancer surgery
1) Gastric resection
The standard surgical procedures for gastric cancer are distal 
subtotal gastrectomy (gastric resection of two-thirds) for cancers in 
the lower or middle third of the stomach and total gastrectomy for 
cancers in the upper or middle third of the stomach, as well as rad-
ical lymphadenectomies. Limited or function-preserving surgeries 
include pylorus-preserving gastrectomy, local resection, segmental 
resection, and proximal gastrectomy. Before performing limited 
surgeries, factors such as the location of the lesion, the extent of 
lymphadenectomy, and resection margins should be considered. 
Proximal gastrectomy is mainly performed for EGCs in the upper 
stomach, but care should be taken to prevent the risk of developing 
reflux esophagitis.41-44
Recommendation: Surgery is the standard treatment for gastric 
cancer. Curative gastric surgery is composed of complete resection 
of the primary lesion with safe margin, radical lymphadenectomy, 
and gastrointestinal reconstruction (Recommendation Grade 1, 
Evidence Level E).
Recommendation: Proximal gastrectomy may replace total gas-
trectomy for limited indications (Recommendation Grade 2, Evi-
dence Level D).
2) Lymphadenectomy
Perigastric lymphadenectomy can be performed in patients 
with EGC. Here, lymph node dissections are performed for group 
1 lymph nodes plus LN7, 8, 9, [+11p].45,46 Peri- and extragastric 
lymphadenectomy is performed in patients with advanced gastric 
cancer (AGC) and patients with EGC who have suspected lymph 
node metastasis. Lymphadenectomy beyond perigastric lymph 
nodes is not currently accepted as a standard therapy, but it is con-
sidered to be an extensive operation. The effects of para-aortic 
lymph node dissection have not been reported.47
Recommendation: In early gastric cancer, the extent of radical 
lymphadenectomy may be reduced. (Recommendation Grade 2, 
Evidence Level D).
3) Combined resection
Combined resection of involved organs can be performed in 
cases showing direct invasion into the adjacent organs,48-58 gastric 
cancers in the greater curvature with muscularis propria invasion, 
suspected splenic hilar lymph node involvement,59-62 suspected dis-
tant metastasis,63-66 and in patients undergoing palliative surgery.
4) Reconstruction
Only a few studies have compared the differences between 
postoperative reconstruction methods. A few studies have com-
pared Billroth-I and Billroth-II and have reported that the 2 types 
of anastomosis did not show significant differences with regard to 
therapeutic performance or difficulty in ingestion.67,68 Additionally, 
Roux-en-Y gastric bypass might be superior to Billroth-I anasto-
mosis in terms of postoperative bilious reflux.69
Recommendation: Gastrojejunostomy, loop gastrojejunostomy and 
Roux-en-Y anastomosis are acceptable reconstruction methods 
after distal gastrectomy (Recommendation Grade 2, Evidence 
Level D).
2. Surgery for early gastric cancers
1) Surgical indications in early gastric cancer 
EGC refers to gastric cancers limited to the mucosal and sub-
mucosal layers regardless of lymph node metastasis; the frequency 
of lymph node metastasis is approximately 5% in mucosal cancers 
and approximately 20% in submucosal cancers.70,71 Any EGC with-
out distant metastasis can be a candidate for surgery which is com-
posed with gastric resection and lymph node dissection.72,73
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2) Open surgery vs. laparoscopic surgery
In most of the retrospective studies of EGC, laparoscopic sur-
gery was not inferior to open surgery.74-84 However, the number of 
prospective studies of laparoscopic surgery is insufficient.85,86
Recommendation: Laparoscopic surgery is acceptable for early 
gastric cancer. (Recommendation Grade 2, Evidence Level C).
3. Surgery for advanced gastric cancer
1) Surgical indications in advanced gastric cancer 
AGC is defined as gastric cancers with invasion into the proper 
muscle and/or deeper layers. In cases with perigastric organ inva-
sion, combined radical resection can be performed. In cases with 
distant metastasis, resection limited to the primary tumor can be 
performed to prevent or treat cancer-related symptoms such as 
bleeding and obstruction, and to improve the quality of life.87-89 In 
unresectable cases, palliative surgeries such as gastrojejunal bypass 
can be performed.90
Endoscopic therapy
1. Absolute indications
Traditionally, the standard treatment for gastric cancer has been 
surgery. Endoscopic mucosal resection, which was first introduced 
in Japan in 1984, and the more recently introduced ESD can replace 
standard surgery if applied to limited stages of EGCs. Endoscopic 
therapy can minimize surgical complications, and the quality of life 
is only slightly affected. In multiple retrospective studies, survival 
after endoscopic treatment is comparable to that after surgery.91-96 
However, according to a Cochrane review, there are no randomized 
controlled trials comparing endoscopic therapy and surgery.97
Theoretically, the indication for endoscopic therapy is EGC 
without risk of lymph node metastasis. However, it is impossible 
to diagnose lymph node metastases accurately before treatment. 
Therefore, indications for endoscopic treatment were defined based 
on the analysis of surgical date of lymph node metastasis.98-102 Cur-
rently, the absolute indications of endoscopic therapy for EGC 
include (1) lesions limited to the mucosal layer, (2) well and/or 
moderately differentiated adenocarcinomas, (3) tumors ≤2 cm in 
length, (4) absence of ulcer or ulcer-scar tissue, and (5) tumors 
without lymphovascular involvement.100 Because it is impossible to 
clearly determine the depth of invasion or lymphovascular involve-
ment, additional treatment is sometimes required based on the 
pathological results. 
Recommendation: Endoscopic therapy can be performed in early 
gastric cancer within absolute indications (Recommendation Grade 
1, Evidence Level D).
2. Expanded indications
With the development of ESD techniques, there have been at-
tempts to extend the indications of endoscopic resection.96,103,104 
Expanded indications include (1) well or moderately differentiated 
adenocarcinoma in the mucosal layer without an ulcer regardless 
of the size, (2) well or moderately differentiated adenocarcinoma 
measuring less than 3 cm in the mucosal layer with ulcer, (3) small 
(less than 2 cm) intramucosal cancer with undifferentiated histol-
ogy, and (4) well or moderately differentiated adenocarcinoma with 
minute submucosal invasion (≤500 μm, SM1).
3. Follow­up
The National Comprehensive Cancer Network guidelines rec-
ommend that follow-up after gastric cancer treatment should be 
conducted every 3 to 6 months for the first three years after R0 
resection. For 3 to 5 years, the follow-up interval is 6 months, and 
there it is yearly. The guideline states that complete blood count, 
biochemical tests, radiologic studies, and endoscopy can be per-
formed if they are clinically necessary.105 The recurrence rate after 
endoscopic therapy for EGC is 3.3% to 14.0%. It is recommended 
that patients should undergo an endoscopic follow-up at least an-
nually because of the risk of missing multiple synchronous cancers.
Recommendation: Endoscopic follow-up is recommended at least 
annually after endoscopic therapy for early gastric cancer (Rec-
ommendation Grade 1, Evidence Level E).
Chemotherapy
1. Postoperative adjuvant chemotherapy for gastric 
cancer
Gastric cancer recurs in 22% to 45% of patients after curative 
resection.106,107 In this regard, there have been many studies that 
evaluated the effect of adjuvant chemotherapy. In meta-analyses 
of clinical trials between 1980 and 2000, adjuvant chemotherapy 
increased the rate of survival.108,109 In 2010, the Global Advanced/
Adjuvant Stomach Tumor Research International Collaboration 
(GASTRIC) group performed a meta-analysis of 17 clinical trials, 
which showed that adjuvant chemotherapy increased the survival 
duration and that fluoropyrimidine-containing therapy lowered the 
Clinical Practice Guidelines for Gastric Cancer in Korea
95
risk of death.110
In a western study, administration of epirubicin+cisplatin+5-
fluorouracil ([5-FU]: ECF) chemotherapy after surgery signifi-
cantly increased the overall survival (hazard ratio [HR], 0.75) and 
disease-free survival (HR, 0.66).111 It is difficult to accept this 
regimen as a standard treatment in Korea because only 42.5% of 
the patients underwent D2 lymph node dissection. In this context, 
clinical studies in Korea and Japan have attempted to determine the 
effect of adjuvant chemotherapy after D2 lymph node dissection. 
Among the 1,059 patients with stage II disease, a comparison was 
made between an S-1 (tegafur+gimeracil+oteracil)-treated group 
and an untreated group after D2 dissection.112 The S-1-treated 
group had a significantly higher 5-year survival rate, compared to 
the surgery-alone group (71.7% vs. 61.1%; HR, 0.669).113 A clinical 
trial (CLASSIC trial) conducted by Korean researchers among 1,035 
patients with stage II, IIIa, and IIIb (T3N2) diseases showed that 
the group treated with capecitabine and oxaliplatin combination 
therapy had a significantly higher 3-year survival rate compared to 
the untreated group (74% vs. 60%).114
In conclusion, S-1 monotherapy and capecitabine+oxaliplatin 
therapy can be standard adjuvant treatments for stage II and III 
diseases after D2 lymph node dissection. In the future, well-de-
signed clinical trials are needed for the development of more effec-
tive postoperative adjuvant therapies.
Recommendation: Adjuvant chemotherapy with either S-1 
monotherapy or capecitabine+oxaliplatin combination therapy can 
be used after surgery for gastric cancer (Recommendation Grade 1, 
Evidence Level B).
2. First­line palliative chemotherapy for recurrent 
and/or metastatic gastric cancer
The main goals of chemotherapy for recurrent and metastatic 
gastric cancers are to prolong the survival and to improve the qual-
ity of life by providing symptom palliation. Since 1990s, 4 small 
randomized Phase III clinical trials that were published115 have 
consistently shown survival benefit (approximately 3 to 7 months) 
and improved quality of life in the patients receiving palliative che-
motherapy, compared to the patients receiving best supportive care 
alone.116-118
Recommendation: First-line palliative chemotherapy is rec-
ommended for recurrent and/or metastatic gastric cancer patients 
in the context of performance status, medical comorbidity and 
toxicity profile (Recommendation Grade 1, Evidence Level B).
Among the gastrointestinal cancers, gastric cancer is known to 
respond relatively well to chemotherapy. Chemotherapeutic agents 
for gastric cancer including 5-FU, mitomycin C, cisplatin, and 
etoposide have shown response rates of at least 10% when admin-
istered as monotherapies. Other newer agents including irinotecan, 
oral etoposide, paclitaxel, docetaxel, and pegylated doxorubicin have 
shown response rates ranging from 10% to 20%. Generally, the re-
sponse rates are low with very short response duration (within 3~4 
months) when anticancer drugs are administered alone. Therefore, 
combination chemotherapies have been attempted in order to in-
crease the response rates and prolong the survival time; in studies 
in which combination chemotherapy was administered, response 
rates of 25% to 50% and median survival of 6 to 12 months have 
been reported.119-122
A recent meta-analysis of randomized trials showed that 
combination chemotherapy significantly improves the survival, 
compared to single chemotherapy or best supportive care alone.115 
First-line palliative chemotherapy with a two-drug combination 
of fluoropyrimidines and platinum is preferred for patients with 
advanced or metastatic disease. Three-drug combination chemo-
therapy with docetaxel or epirubicin should be reserved for medi-
cally fit patients with a good performance status. 
Recently, molecular targeted agents such as trastuzumab, be-
vacizumab, cetuximab, and lapatinib have been tested with the 
standard chemotherapy for recurrent and metastatic gastric cancers. 
Based on the results of the ToGA study, which showed a signifi-
cant improvement in the median overall survival (13.5 vs. 11.1 
months) with the addition of trastuzumab to chemotherapy (5-FU 
or capecitabine and cisplatin), trastuzumab in combination with 
chemotherapy is recommended for patients having HER2 over-
expression or amplification (HER2 IHC 3+ or HER2 IHC 2+ with 
FISH/SISH+).123 However, the addition of either bevacizumab,124 
cetuximab,125 or lapatinib126 to chemotherapy failed to show survival 
benefit in recent phase III clinical trials. 
Recommendation: First-line palliative chemotherapy regimens 
include fluoropyrimidines (5-FU, capecitabine, S-1), platinums 
(cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), irinotecan 
and anthracyclines (doxorubicin, epirubicin). Single or combina-
tion (two or three drugs) therapy can be given (Recommendation 
Grade 1-2, Evidence Level B-C).
Preferred regimens for first-line chemotherapy include 
DCF (docetaxel, cisplatin, and 5-FU) and its modification 
(1B), ECF and its modification (1B), fluoropyrimidines (5-
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FU, capecitabine, or S-1)+cisplatin (1B), fluoropyrimidines 
(5-FU or capecitabine)+oxaliplatin (2B), fluoropyrimidines 
(5-FU)+irinotecan (2C), taxanes (docetaxel or paclitaxel)+cisplatin 
(2C), and trastuzumab with fluoropyrimidines (5-FU or 
capecitabine)+cisplatin for HER2-overexpressing adenocarcinomas 
(1B). Single agent chemotherapy using fluoropyrimidines (5-FU, 
capecitabine, or S-1; 2C) can be given for patients who are medi-
cally unfit for receiving combination chemotherapy. 
3. Second­line palliative chemotherapy for recurrent 
and/or metastatic gastric cancer
A complete cure cannot be expected in recurrent/metastatic 
gastric cancer patients. Instead, an extended survival period and 
alleviation of symptoms can be expected with chemotherapy. 
However, there are no established results for second-line palliative 
chemotherapy, although progressive diseases have been detected in 
many patients who received first-line palliative chemotherapy. 
Recently, 2 randomized phase III clinical trials reported sig-
nificantly extended survival durations after second-line pallia-
tive chemotherapy compared to best supportive care in advanced 
patients who had received first-line palliative chemotherapy for 
metastatic gastric cancer.127,128 Among these patients (Eastern Co-
operative Oncology Group performance statuses: mostly 0 to 2), 
the group that received irinotecan or docetaxel as a second-line 
palliative chemotherapy agent showed a significant increase in the 
overall survival duration compared to the group that received best 
supportive care. A meta-analysis of the results from these 2 studies 
showed that second-line chemotherapy had a significant effect on 
survival duration when compared to best supportive care (HR, 0.52; 
95% confidence interval, 0.30~0.90).
Recommendation: In cases of recurrent and/or metastatic gastric 
cancer after first-line palliative chemotherapy, second-line pal-
liative chemotherapy is recommended if the patient’s performance 
status is good (Recommendation Grade 1, Evidence Level B).
Although a standard second-line palliative chemotherapy has 
not been established for advanced cancer, the type, dosage, and 
administration method of second-line chemotherapy should be 
determined after consideration of the toxicity of the intended 
agent, differences between patients, the first-line chemotherapy 
type, performance status, accompanying diseases, available agents, 
and economic aspects. For second-line palliative chemotherapy, 
regimens based on existing phase II clinical trial results can be ad-
opted or regimens from well-designed clinical trials can be used. 
The recommended second-line palliative chemotherapies, based 
on clinical trial results, include paclitaxel-based chemotherapies 
(paclitaxel; paclitaxel with doxifluridine, capecitabine, or 5-FU and 
leucovorin; and paclitaxel with cisplatin or carboplatin), docetaxel-
based chemotherapies (docetaxel; docetaxel with cisplatin or oxali-
platin; docetaxel with 5-FU or capecitabine; docetaxel with etopo-
side; docetaxel with epirubicin; and DCF if not used as a first-line 
therapy), irinotecan-based chemotherapies (irinotecan; irinotecan 
with cisplatin; irinotecan with 5-FU and leucovorin or capecitabi-
ne; and irinotecan with mitomycin), platinum-based chemothera-
pies (5-FU or capecitabine with cisplatin; 5-FU or capecitabine 
with cisplatin and trastuzumab for Her2-neu overexpressing ad-
enocarcinomas if not used as a first-line therapy; fluoropyrimidine 
[capecitabine or 5-FU and leucovorin] with oxaliplatin; pegylated 
liposomal doxorubicin with oxaliplatin; and epirubicin, cisplatin 
and 5-FU [ECF] or epirubicin, cisplatin and capecitabine [ECX] 
if not used as a first line therapy), fluoropyrimidine-based che-
motherapies (fluoropyrimidine [S-1, capecitabine, or 5-FU] and 
leucovorin); fluoropyrimidine [S-1 or 5-FU and leucovorin] with 
mitomycin; 5-FU with methotrexate; and capecitabine with doxo-
rubicin).
Radiation therapy
1. Neoadjuvant radiation therapy
Neoadjuvant radiation therapy can be performed before surgery 
to increase the possibility of performing radical resection in patients 
with locally advanced gastric cancer. To date, there have been three 
randomized controlled trials regarding neoadjuvant radiation thera-
py. Zhang et al.129 reported a significant increases in the 5- and 10-
year overall survival and resection rates in neoadjuvant radiation 
therapy group compared to surgery alone group, when 370 patients 
with gastric adenocarcinomas located in the gastric cardia were 
compared. Skoropad et al.130,131 reported that neoadjuvant radiation 
therapy tended to increase survival rates among patients with pre-
operatively positive lymph node metastases or clinical T3 or higher 
stage.
Recommendation: Neoadjuvant radiation therapy may be consid-
ered in patients with locally advanced gastric cancer (Recommen-
dation Grade 2, Evidence Level C).
2. Adjuvant radiation therapy
Adjuvant radiation therapy can be performed alone or in 
combination with chemotherapy if there is a possibility of recur-
rence after curative resection. Postoperative recurrences are mainly 
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divided into local recurrences, regional recurrences, and distant 
metastases. Among these, local and regional recurrences can be 
reduced with adjuvant radiation therapy and eventually the cure 
rate can be increased. There have been several studies which have 
compared surgery alone with surgery plus postoperative adjuvant 
chemoradiotherapy in gastric cancer patients who underwent cura-
tive resection.
According to the result of a randomized controlled trial in 556 
patients, conducted by Macdonald et al.,132 the adjuvant chemora-
diotherapy group showed increased survival duration compared to 
surgery alone group. However, lymph node dissection was either 
not performed at all or was only partially performed in 90% of the 
patients, and this limitation made it difficult to apply the findings of 
this study to the patients in Korea, where D2 lymph node dissection 
is considered a standard treatment. Therefore, this study showed 
that adjuvant chemoradiotherapy would increase the survival period 
for gastric cancer patients without extended lymph node dissection.   
An observation study of 990 patients who underwent D2 lymph 
node dissection, conducted by Kim et al.,133 showed that adjuvant 
chemoradiotherapy resulted in a reduced recurrence rate and a bet-
ter survival rate compared to that in surgery alone group. Therefore, 
adjuvant chemoradiotherapy can be considered as a postoperative 
adjuvant therapy for gastric cancer patients, including those who 
have undergone D2 lymph node dissection. Meanwhile, according 
the results of an observational study conducted by Dikken et al.,134 
adjuvant chemoradiotherapy reduced the local recurrence rate after 
D1 lymph node dissection, but no difference was observed after D2 
lymph node dissection. Hence, a randomized phase 3 clinical study 
is needed to determine the effects of adjuvant chemoradiotherapy 
after extended lymph node dissection.
Recommendation: Chemoradiotherapy may be considered as a 
postoperative adjuvant therapy for radically resected gastric cancer 
patients (Recommendation Grade 2, Evidence Level C).
Although it is not possible to obtain a curative effect, palliative 
radiation therapy can be used to alleviate patients’ symptoms and 
to increase the quality of life of patients. Palliative radiation therapy 
can be applied to reduce severe bleeding or difficulty in swallow-
ing caused by stomach cancers and severe pain due to metastasis to 
other organs (e.g., brain, bone, and abdomen).
Pathologic evaluation
1. Handling of gastric cancer specimens
Gastric cancer specimens are obtained by endoscopic biopsy, 
endoscopic resection including polypectomy, and surgical resec-
tion. In case of endoscopic biopsy, the biopsy sites and number of 
specimens should be clearly defined. For the pathologic evaluation 
of endoscopic mucosal resection (EMR) or ESD specimens, the 
samples should be spread on a plate without overstretching, fixed 
with a pin to prevent contraction, and placed in formalin. Mapping 
can be performed when the specimen is submitted properly. The 
guideline items of pathologic diagnosis are described only when 
mapping is performed. If mapping is not possible, only the histo-
logical classification and differentiation can be mentioned in the 
pathologic report. Surgically resected specimens should be opened 
along the greater or lesser curvature of stomach without caus-
ing damage to the lesion. The specimen should be stretched and 
pinned onto a plate to prevent contraction. The stomach should be 
immediately fixed in 10% neutral formalin for routine microscopic 
examination. The amount of fixative should be sufficient to com-
pletely submerge the specimens. At least 3 to 4 hours are required 
to fix biopsies and at least 8 hours are required to fix the resection 
samples. Fixed specimens should be cut into sections according 
to the recommendations of the Gastrointestinal Pathology Study 
Group of Korean Society of Pathologists.135 For frozen section or 
tissue banking, the use of a fresh unfixed tissue is recommended.
2. Pathologic diagnosis of gastric cancer
The World Health Organization classification136 is used for his-
tological classification of gastric cancers, and Lauren classification137 
can be added in it. If histological classification is difficult, immu-
nohistochemical or histochemical staining will be helpful. Tubular 
adenocarcinomas should be classified according to the grade of 
differentiation, for which the 2-, 3-, or 4-tier grading system can 
be used. Generally, the 3-tier grading system is used.
Grade 1: Well differentiated; ＞95% gland forming
Grade 2: Moderately differentiated; 50%~95% gland forming
Grade 3: Poorly differentiated; 0%~49% gland forming
The following items should be included in the pathologic report, 
along with optional information according to the recommendations 
of the Gastrointestinal Pathology Study Group of Korean Society of 
Pathologists.138 For the following items in the pathological report, 
all processes should be performed properly including prescribing, 
tissue processing, and diagnosis. Additional reasonable prescriptions 
and tests should be added for providing more information. The 
pathologic staging for gastric cancer is based on the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual, 7th edi-
tion.139
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Biopsy: Histological classification, differentiation
Endoscopic resection*: Histological classification, differentiation, 
tumor size, depth of invasion, presence of lymphatic vascular 
invasion, resection margin status
Surgery: Histological classification, differentiation, tumor size, 
depth of invasion, proximal and distal resection margins, num-
ber of resected regional lymph nodes, number of lymph nodes 
with tumor invasion 
*The items can be described only when the pathologic interpre-
tation is possible after mapping.
3. Pathologic evaluation of lymph node metastasis
Accurate pathologic evaluation of lymph nodes is mandatory 
for cancer staging. As many lymph nodes as possible should be 
microscopically examined in the radically resected specimens. The 
pN staging is determined using the conventional hematoxylin and 
eosin stain. Tumor staging is based on the AJCC staging system.139
4. Pathologic markers associated with targeted 
agents for gastric cancer 
Some changes in the protein or gene expression in gastric can-
cers are recognized as important prognostic and therapeutic mark-
ers. Immunohistochemical staining is one of the useful methods for 
detecting the change in protein expression. For targeted therapy, 
Her2 protein expression tests or gene amplification tests are neces-
sary for selecting gastric or gastroesophageal cancer patients. When 
the score of immunohistochemical staining for Her2 is 3+, targeted 
therapy is indicated. In case the score of immunohistochemical 
staining for Her2 is 2+, an additional FISH (or SISH) test is rec-
ommended. However, even when the score of immunohistochemi-
cal staining for Her2 is 0 or 1+, Her2 gene amplification is present 
in 2% to 11% of patients by FISH (or SISH). Therefore, the FISH 
(or SISH) test is not meaningless even when the immunohisto-
chemical staining score is 0 or 1+.140-144
Recommendation: Her2 protein expression or gene amplification 
tests are useful in the management of gastric or gastroesophageal 
cancer patients (Recommendation Grade 1, Evidence Level B).
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